Merck Stock News

Dow Jones Industrial Average (DJI) components Caterpillar Inc. (NYSE:CAT) and Merck & Co Inc (NYSE:MRK) are moving in opposite directions today after their respective first-quarter earnings reports, a

Merck (MRK) beats first-quarter estimates for earnings and sales. The company raises its EPS range for 2024.

Merck (MRK) shares advanced in intraday trading Thursday after the pharmaceutical firm reported better-than-expected quarterly results, and raised and narrowed its guidance on strong sales of its bloc

Although the revenue and EPS for Merck (MRK) give a sense of how its business performed in the quarter ended March 2024, it might be worth considering how some key metrics compare with Wall Street est

Merck & Co Inc (NYSE:MRK, ETR:6MK), the pharmaceutical firm, saw its shares tick 3.5% higher after its cancer drug Keytruda helped it post a profit and sales beat. Revenues during the group's first qu

Merck & Co on Thursday raised its annual profit and revenue forecast on the back of strong sales for its blockbuster cancer drug Keytruda and human papillomavirus (HPV) vaccine Gardasil.

The first-quarter results come as Merck shows substantial progress in preparing for Keytruda's patent expiration in 2028.

Merck & Co. Inc. on Thursday reported first-quarter results that beat analysts' expectations amid strong sales of vaccines and cancer drug Keytruda.

While the healthcare sector is expected to benefit from cutting-edge medicines, new drug approvals, technological advancements, and deal activities, it is expected to witness a modest earnings decline

Drug and biotech companies are likely to see significant innovation. In the Large-Cap Pharmaceuticals industry, Eli Lilly (LLY), Novo Nordisk (NVO), Merck (MRK) and AbbVie (ABBV) are worth retaining i

Let's look at five biotech/drug companies, MRK, SNY, BMY, GILD and ABBV, slated to release their first quarter 2024 earnings results this week.

Merck (NYSE: MRK) will report its Q1 2024 results on Thursday, April 25. We expect the company to post revenue of $15.2 billion and adjusted earnings of $1.97, slightly ahead of the street estimates.

As an investor with significant positions in equities, I am an optimist. However, it's important to be realistic at the same time.

Big money tends to flow from one sector to the other. During the pandemic, sectors like pharmaceutical and e-commerce were hot.

Investor focus is likely to be on the sales of Merck's (MRK) blockbuster oncology medicine, Keytruda, when the company reports first-quarter 2024 earnings.